




Curriculum Vitae

| Personal Information | |
|--|---|
| Title | Dr. |
| Name | Xian-rui Wu |
| Degree | MD, PhD |
| Country | China |
| Affiliation | The Sixth Affiliated Hospital, Sun Yat-sen University |
|  | |
| Educational Background | |
| <p>2003—2008 Zhongshan School of Medicine, Sun Yat-sen University, MD 2008—2013 The Sixth Affiliated Hospital, Sun Yat-sen University, PhD 2011—2014 Department of Colorectal Surgery, Cleveland Clinic, Research Fellow 2014—2017 The Sixth Affiliated Hospital, Sun Yat-sen University, Resident and Fellow 2018—2020 The Sixth Affiliated Hospital, Sun Yat-sen University, Associate Professor/Staff 2021—Now The Sixth Affiliated Hospital, Sun Yat-sen University, Professor/Staff</p> | |
| Professional Experience | |
| <p>Dr. Xian-rui Wu is a professor/surgeon in the Department of Colorectal Surgery. He specializes in the surgical treatment of colorectal cancer (CRC) and inflammatory bowel disease (IBD), particularly the minimally invasive surgery. His research interests focus on investigating the role of immune microenvironment in the pathogenesis of CRC and IBD.</p> | |
| Professional Organizations | |
| <p>Member, Chinese Association of Colorectal Surgery, Chinese Medical Doctors Association</p> | |
| Main Scientific Publications | |
| <p>Dr. Xian-rui Wu has published more than 100 peer-reviewed English articles.</p> <ol style="list-style-type: none"> Chen B, Wu X, Ruan Y, Zhang Y, Cai Q, Zapata L, Wu CI, Lan P, Wen H. Very large hidden genetic diversity in one single tumor— Evidence for tumors-in-tumor. <i>National Science Review</i>. 2022. (Accepted) Wu Q, Yue X, Liu H, Zhu Y, Ke H, Yang X, Yin S, Li Z, Zhang Y, Hu T, Lan P, Wu X. MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. <i>Mol Ther</i>. 2022. Online ahead of print. Liang ZX, Liu HS, Xiong L, Zeng ZW, Zheng XB, Kang L, Lan P, Wu XR. GAS6 from CD200+ adipose-derived stem cells mitigates colonic inflammation via a macrophage-dependent manner. <i>J Crohns Colitis</i>. 2022. Online ahead of print. Huang JH, Liu HS, Hu T, Zhang ZJ, He XW, Mo TW, Wen XF, Lan P, Lian L, Wu XR. Elevated preoperative CA125 is associated with poor survival in patients with metastatic colorectal cancer undergoing primary tumor resection: a retrospective cohort study. <i>Gastroenterol Rep (Oxf)</i>. 2022 Jun 14;10:goac020. Wu X, Zhang Y, Hu T, He X, Zou Y, Deng Q, Ke J, Lian L, He X, Zhao D, Cai X, Chen Z, Wu X, Fan JB, Gao F, Lan P. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. <i>Mol Oncol</i>. 2021 Mar 11. Liang ZX, Liu HS, Xiong L, Yang X, Wang FW, Zeng ZW, He XW, Wu XR, Lan P. A novel NF-κB | |



regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation. *Mol Cancer*. 2021 Aug 19;20(1):103.

7. Liang Z, Liu H, Zhang Y, Xiong L, Zeng Z, He X, Wang F, Wu X, Lan P. Cyr61 from adipose-derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin α V β 5. *Mol Oncol*. 2021;15(12):3447-3467.

8. Sui J, Wu X, Wang C, Wang G, Li C, Zhao J, Zhang Y, Xiang J, Xu Y, Nian W, Cao F, Yu G, Lou Z, Hao L, Liu L, Li B, Zhang Z, Cai S, Liu H, Lan P, Zhang W. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study. *Clin Epigenetics*. 2021 Feb 3;13(1):26.

9. Zhang Y, Wu Q, Xu L, Wang H, Liu X, Li S, Hu T, Liu Y, Peng Q, Chen Z, Wu X, Fan JB. Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay. *Clin Epigenetics*. 2021 Apr 23;13(1):90.

10. Liu H, Liang Z, Zhou C, Zeng Z, Wang F, Hu T, He X, Wu X, Wu X, Lan P. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. *Signal Transduct Target Ther*. 2021 Apr 9;6(1):144.